Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Generic Biologics Policy May Be One Change Under McClellan

Executive Summary

FDA Commissioner-designate Mark McClellan appears to be open to establishing a generic approval system for biological products

You may also be interested in...



Generic Biologics Are Coming, Commissioner McClellan Tells MBC

Biogen is understood to be drafting a position statement on generic biologics on behalf of the Massachusetts Biotechnology Council

Generic Biologics Are Coming, Commissioner McClellan Tells MBC

Biogen is understood to be drafting a position statement on generic biologics on behalf of the Massachusetts Biotechnology Council

Generic Biologics: Xigris Approval Suggests Precedent For FDA, GPhA Says

FDA's analysis of manufacturing process changes for Xigris is the latest indication that some form of a generic biologics approval process is feasible, the Generic Pharmaceutical Association says

Related Content

UsernamePublicRestriction

Register

PS040613

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel